Literature DB >> 28130160

Chelerythrine promotes Ca2+-dependent calpain activation in neuronal cells in a PKC-independent manner.

Ana Saavedra1, Sara Fernández-García2, Silvia Cases3, Mar Puigdellívol2, Rafael Alcalá-Vida2, Núria Martín-Flores3, Jordi Alberch2, Silvia Ginés2, Cristina Malagelada3, Esther Pérez-Navarro4.   

Abstract

BACKGROUND: Chelerythrine is widely used as a broad range protein kinase C (PKC) inhibitor, but there is controversy about its inhibitory effect. Moreover, it has been shown to exert PKC-independent effects on non-neuronal cells.
METHODS: In this study we investigated possible off-target effects of chelerythrine on cultured cortical rodent neurons and a neuronal cell line.
RESULTS: We found that 10μM chelerythrine, a commonly used concentration in neuronal cultures, reduces PKC and cAMP-dependent protein kinase substrates phosphorylation in mouse cultured cortical neurons, but not in rat primary cortical neurons or in a striatal cell line. Furthermore, we found that incubation with chelerythrine increases pERK1/2 levels in all models studied. Moreover, our results show that chelerythrine promotes calpain activation as assessed by the cleavage of spectrin, striatal-enriched protein tyrosine phosphatase and calcineurin A. Remarkably, chelerythrine induces a concentration-dependent increase in intracellular Ca2+ levels that mediates calpain activation. In addition, we found that chelerythrine induces ERK1/2- and calpain-independent caspase-3 activation that can be prevented by the Ca2+ chelator BAPTA-AM.
CONCLUSIONS: This is the first report showing that chelerythrine promotes Ca2+-dependent calpain activation in neuronal cells, which has consequences for the interpretation of studies using this compound. GENERAL SIGNIFICANCE: Chelerythrine is still marketed as a specific PKC inhibitor and extensively used in signal transduction studies. We believe that the described off-target effects should preclude its use as a PKC inhibitor in future works.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cleaved caspase-3; ERK1/2; PKA; Spectrin breakdown products; Striatal-enriched protein tyrosine phosphatase

Mesh:

Substances:

Year:  2017        PMID: 28130160     DOI: 10.1016/j.bbagen.2017.01.021

Source DB:  PubMed          Journal:  Biochim Biophys Acta Gen Subj        ISSN: 0304-4165            Impact factor:   3.770


  6 in total

1.  Proteolytic Degradation of Hippocampal STEP61 in LTP and Learning.

Authors:  Ana Saavedra; Jesús J Ballesteros; Shiraz Tyebji; Sara Martínez-Torres; Gloria Blázquez; Rosa López-Hidalgo; Garikoitz Azkona; Jordi Alberch; Eduardo D Martín; Esther Pérez-Navarro
Journal:  Mol Neurobiol       Date:  2018-06-12       Impact factor: 5.590

Review 2.  Role of Protein Kinase C in Bipolar Disorder: A Review of the Current Literature.

Authors:  Ashwini Saxena; Giselli Scaini; Daniela V Bavaresco; Camila Leite; Samira S Valvassori; André F Carvalho; João Quevedo
Journal:  Mol Neuropsychiatry       Date:  2017-10-07

Review 3.  Interaction of the putative anticancer alkaloid chelerythrine with nucleic acids: biophysical perspectives.

Authors:  Anirban Basu; Gopinatha Suresh Kumar
Journal:  Biophys Rev       Date:  2020-10-31

4.  Natural Protein Kinase Inhibitors, Staurosporine, and Chelerythrine Suppress Wheat Blast Disease Caused by Magnaporthe oryzae Triticum.

Authors:  Moutoshi Chakraborty; S M Fajle Rabby; Dipali Rani Gupta; Mahfuzur Rahman; Sanjoy Kumar Paul; Nur Uddin Mahmud; Abdullah Al Mahbub Rahat; Ljupcho Jankuloski; Tofazzal Islam
Journal:  Microorganisms       Date:  2022-06-09

5.  Virtual Screening of Alkaloid and Terpenoid Inhibitors of SMT Expressed in Naegleria sp.

Authors:  Jason Abraham; Neha Chauhan; Supriyo Ray
Journal:  Molecules       Date:  2022-09-05       Impact factor: 4.927

Review 6.  Equivocal, explicit and emergent actions of PKC isoforms in cancer.

Authors:  Peter J Parker; Sophie J Brown; Veronique Calleja; Probir Chakravarty; Mathias Cobbaut; Mark Linch; Jacqueline J T Marshall; Silvia Martini; Neil Q McDonald; Tanya Soliman; Lisa Watson
Journal:  Nat Rev Cancer       Date:  2020-11-11       Impact factor: 60.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.